Long-term impact of fecal transplantation in healthy volunteers

Abstract Background Fecal microbiota transplantation (FMT) has been recently approved by FDA for the treatment of refractory recurrent clostridial colitis (rCDI). Success of FTM in treatment of rCDI led to a number of studies investigating the effectiveness of its application in the other gastrointe...

Full description

Bibliographic Details
Main Authors: Oleg V. Goloshchapov, Evgenii I. Olekhnovich, Sergey V. Sidorenko, Ivan S. Moiseev, Maxim A. Kucher, Dmitry E. Fedorov, Alexander V. Pavlenko, Alexander I. Manolov, Vladimir V. Gostev, Vladimir A. Veselovsky, Ksenia M. Klimina, Elena S. Kostryukova, Evgeny A. Bakin, Alexander N. Shvetcov, Elvira D. Gumbatova, Ruslana V. Klementeva, Alexander A. Shcherbakov, Margarita V. Gorchakova, Juan José Egozcue, Vera Pawlowsky-Glahn, Maria A. Suvorova, Alexey B. Chukhlovin, Vadim M. Govorun, Elena N. Ilina, Boris V. Afanasyev
Format: Article
Language:English
Published: BMC 2019-12-01
Series:BMC Microbiology
Subjects:
Online Access:https://doi.org/10.1186/s12866-019-1689-y
id doaj-78f30b949a854bfb94166405a8166d93
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Oleg V. Goloshchapov
Evgenii I. Olekhnovich
Sergey V. Sidorenko
Ivan S. Moiseev
Maxim A. Kucher
Dmitry E. Fedorov
Alexander V. Pavlenko
Alexander I. Manolov
Vladimir V. Gostev
Vladimir A. Veselovsky
Ksenia M. Klimina
Elena S. Kostryukova
Evgeny A. Bakin
Alexander N. Shvetcov
Elvira D. Gumbatova
Ruslana V. Klementeva
Alexander A. Shcherbakov
Margarita V. Gorchakova
Juan José Egozcue
Vera Pawlowsky-Glahn
Maria A. Suvorova
Alexey B. Chukhlovin
Vadim M. Govorun
Elena N. Ilina
Boris V. Afanasyev
spellingShingle Oleg V. Goloshchapov
Evgenii I. Olekhnovich
Sergey V. Sidorenko
Ivan S. Moiseev
Maxim A. Kucher
Dmitry E. Fedorov
Alexander V. Pavlenko
Alexander I. Manolov
Vladimir V. Gostev
Vladimir A. Veselovsky
Ksenia M. Klimina
Elena S. Kostryukova
Evgeny A. Bakin
Alexander N. Shvetcov
Elvira D. Gumbatova
Ruslana V. Klementeva
Alexander A. Shcherbakov
Margarita V. Gorchakova
Juan José Egozcue
Vera Pawlowsky-Glahn
Maria A. Suvorova
Alexey B. Chukhlovin
Vadim M. Govorun
Elena N. Ilina
Boris V. Afanasyev
Long-term impact of fecal transplantation in healthy volunteers
BMC Microbiology
Fecal microbiota transplantation
Healthy volunteers
Metagenomics
16S rRNA gene sequencing
Shotgun sequencing
Metagenome-assembled genome
author_facet Oleg V. Goloshchapov
Evgenii I. Olekhnovich
Sergey V. Sidorenko
Ivan S. Moiseev
Maxim A. Kucher
Dmitry E. Fedorov
Alexander V. Pavlenko
Alexander I. Manolov
Vladimir V. Gostev
Vladimir A. Veselovsky
Ksenia M. Klimina
Elena S. Kostryukova
Evgeny A. Bakin
Alexander N. Shvetcov
Elvira D. Gumbatova
Ruslana V. Klementeva
Alexander A. Shcherbakov
Margarita V. Gorchakova
Juan José Egozcue
Vera Pawlowsky-Glahn
Maria A. Suvorova
Alexey B. Chukhlovin
Vadim M. Govorun
Elena N. Ilina
Boris V. Afanasyev
author_sort Oleg V. Goloshchapov
title Long-term impact of fecal transplantation in healthy volunteers
title_short Long-term impact of fecal transplantation in healthy volunteers
title_full Long-term impact of fecal transplantation in healthy volunteers
title_fullStr Long-term impact of fecal transplantation in healthy volunteers
title_full_unstemmed Long-term impact of fecal transplantation in healthy volunteers
title_sort long-term impact of fecal transplantation in healthy volunteers
publisher BMC
series BMC Microbiology
issn 1471-2180
publishDate 2019-12-01
description Abstract Background Fecal microbiota transplantation (FMT) has been recently approved by FDA for the treatment of refractory recurrent clostridial colitis (rCDI). Success of FTM in treatment of rCDI led to a number of studies investigating the effectiveness of its application in the other gastrointestinal diseases. However, in the majority of studies the effects of FMT were evaluated on the patients with initially altered microbiota. The aim of our study was to estimate effects of FMT on the gut microbiota composition in healthy volunteers and to monitor its long-term outcomes. Results We have performed a combined analysis of three healthy volunteers before and after capsule FMT by evaluating their general condition, adverse clinical effects, changes of basic laboratory parameters, and several immune markers. Intestinal microbiota samples were evaluated by 16S rRNA gene and shotgun sequencing. The data analysis demonstrated profound shift towards the donor microbiota taxonomic composition in all volunteers. Following FMT, all the volunteers exhibited gut colonization with donor gut bacteria and persistence of this effect for almost ∼1 year of observation. Transient changes of immune parameters were consistent with suppression of T-cell cytotoxicity. FMT was well tolerated with mild gastrointestinal adverse events, however, one volunteer developed a systemic inflammatory response syndrome. Conclusions The FMT leads to significant long-term changes of the gut microbiota in healthy volunteers with the shift towards donor microbiota composition and represents a relatively safe procedure to the recipients without long-term adverse events.
topic Fecal microbiota transplantation
Healthy volunteers
Metagenomics
16S rRNA gene sequencing
Shotgun sequencing
Metagenome-assembled genome
url https://doi.org/10.1186/s12866-019-1689-y
work_keys_str_mv AT olegvgoloshchapov longtermimpactoffecaltransplantationinhealthyvolunteers
AT evgeniiiolekhnovich longtermimpactoffecaltransplantationinhealthyvolunteers
AT sergeyvsidorenko longtermimpactoffecaltransplantationinhealthyvolunteers
AT ivansmoiseev longtermimpactoffecaltransplantationinhealthyvolunteers
AT maximakucher longtermimpactoffecaltransplantationinhealthyvolunteers
AT dmitryefedorov longtermimpactoffecaltransplantationinhealthyvolunteers
AT alexandervpavlenko longtermimpactoffecaltransplantationinhealthyvolunteers
AT alexanderimanolov longtermimpactoffecaltransplantationinhealthyvolunteers
AT vladimirvgostev longtermimpactoffecaltransplantationinhealthyvolunteers
AT vladimiraveselovsky longtermimpactoffecaltransplantationinhealthyvolunteers
AT kseniamklimina longtermimpactoffecaltransplantationinhealthyvolunteers
AT elenaskostryukova longtermimpactoffecaltransplantationinhealthyvolunteers
AT evgenyabakin longtermimpactoffecaltransplantationinhealthyvolunteers
AT alexandernshvetcov longtermimpactoffecaltransplantationinhealthyvolunteers
AT elviradgumbatova longtermimpactoffecaltransplantationinhealthyvolunteers
AT ruslanavklementeva longtermimpactoffecaltransplantationinhealthyvolunteers
AT alexanderashcherbakov longtermimpactoffecaltransplantationinhealthyvolunteers
AT margaritavgorchakova longtermimpactoffecaltransplantationinhealthyvolunteers
AT juanjoseegozcue longtermimpactoffecaltransplantationinhealthyvolunteers
AT verapawlowskyglahn longtermimpactoffecaltransplantationinhealthyvolunteers
AT mariaasuvorova longtermimpactoffecaltransplantationinhealthyvolunteers
AT alexeybchukhlovin longtermimpactoffecaltransplantationinhealthyvolunteers
AT vadimmgovorun longtermimpactoffecaltransplantationinhealthyvolunteers
AT elenanilina longtermimpactoffecaltransplantationinhealthyvolunteers
AT borisvafanasyev longtermimpactoffecaltransplantationinhealthyvolunteers
_version_ 1724350716100739072
spelling doaj-78f30b949a854bfb94166405a8166d932021-01-03T12:09:07ZengBMCBMC Microbiology1471-21802019-12-0119111310.1186/s12866-019-1689-yLong-term impact of fecal transplantation in healthy volunteersOleg V. Goloshchapov0Evgenii I. Olekhnovich1Sergey V. Sidorenko2Ivan S. Moiseev3Maxim A. Kucher4Dmitry E. Fedorov5Alexander V. Pavlenko6Alexander I. Manolov7Vladimir V. Gostev8Vladimir A. Veselovsky9Ksenia M. Klimina10Elena S. Kostryukova11Evgeny A. Bakin12Alexander N. Shvetcov13Elvira D. Gumbatova14Ruslana V. Klementeva15Alexander A. Shcherbakov16Margarita V. Gorchakova17Juan José Egozcue18Vera Pawlowsky-Glahn19Maria A. Suvorova20Alexey B. Chukhlovin21Vadim M. Govorun22Elena N. Ilina23Boris V. Afanasyev24R.M.Gorbacheva Memorial Institute of Oncology, Hematology and Transplantation, Pavlov First Saint Petersburg State Medical UniversityFederal Research and Clinical Centre of Physical and Chemical Medicine of Federal Medical and Biological Agency of RussiaPediatric Research and Clinical Center for Infectious DiseasesR.M.Gorbacheva Memorial Institute of Oncology, Hematology and Transplantation, Pavlov First Saint Petersburg State Medical UniversityR.M.Gorbacheva Memorial Institute of Oncology, Hematology and Transplantation, Pavlov First Saint Petersburg State Medical UniversityFederal Research and Clinical Centre of Physical and Chemical Medicine of Federal Medical and Biological Agency of RussiaFederal Research and Clinical Centre of Physical and Chemical Medicine of Federal Medical and Biological Agency of RussiaFederal Research and Clinical Centre of Physical and Chemical Medicine of Federal Medical and Biological Agency of RussiaPediatric Research and Clinical Center for Infectious DiseasesFederal Research and Clinical Centre of Physical and Chemical Medicine of Federal Medical and Biological Agency of RussiaFederal Research and Clinical Centre of Physical and Chemical Medicine of Federal Medical and Biological Agency of RussiaFederal Research and Clinical Centre of Physical and Chemical Medicine of Federal Medical and Biological Agency of RussiaR.M.Gorbacheva Memorial Institute of Oncology, Hematology and Transplantation, Pavlov First Saint Petersburg State Medical UniversityR.M.Gorbacheva Memorial Institute of Oncology, Hematology and Transplantation, Pavlov First Saint Petersburg State Medical UniversityR.M.Gorbacheva Memorial Institute of Oncology, Hematology and Transplantation, Pavlov First Saint Petersburg State Medical UniversityR.M.Gorbacheva Memorial Institute of Oncology, Hematology and Transplantation, Pavlov First Saint Petersburg State Medical UniversityR.M.Gorbacheva Memorial Institute of Oncology, Hematology and Transplantation, Pavlov First Saint Petersburg State Medical UniversityR.M.Gorbacheva Memorial Institute of Oncology, Hematology and Transplantation, Pavlov First Saint Petersburg State Medical UniversityUniversitat Politècnica de CatalunyaUniversitat de GironaExplana Research LaboratoryR.M.Gorbacheva Memorial Institute of Oncology, Hematology and Transplantation, Pavlov First Saint Petersburg State Medical UniversityFederal Research and Clinical Centre of Physical and Chemical Medicine of Federal Medical and Biological Agency of RussiaFederal Research and Clinical Centre of Physical and Chemical Medicine of Federal Medical and Biological Agency of RussiaR.M.Gorbacheva Memorial Institute of Oncology, Hematology and Transplantation, Pavlov First Saint Petersburg State Medical UniversityAbstract Background Fecal microbiota transplantation (FMT) has been recently approved by FDA for the treatment of refractory recurrent clostridial colitis (rCDI). Success of FTM in treatment of rCDI led to a number of studies investigating the effectiveness of its application in the other gastrointestinal diseases. However, in the majority of studies the effects of FMT were evaluated on the patients with initially altered microbiota. The aim of our study was to estimate effects of FMT on the gut microbiota composition in healthy volunteers and to monitor its long-term outcomes. Results We have performed a combined analysis of three healthy volunteers before and after capsule FMT by evaluating their general condition, adverse clinical effects, changes of basic laboratory parameters, and several immune markers. Intestinal microbiota samples were evaluated by 16S rRNA gene and shotgun sequencing. The data analysis demonstrated profound shift towards the donor microbiota taxonomic composition in all volunteers. Following FMT, all the volunteers exhibited gut colonization with donor gut bacteria and persistence of this effect for almost ∼1 year of observation. Transient changes of immune parameters were consistent with suppression of T-cell cytotoxicity. FMT was well tolerated with mild gastrointestinal adverse events, however, one volunteer developed a systemic inflammatory response syndrome. Conclusions The FMT leads to significant long-term changes of the gut microbiota in healthy volunteers with the shift towards donor microbiota composition and represents a relatively safe procedure to the recipients without long-term adverse events.https://doi.org/10.1186/s12866-019-1689-yFecal microbiota transplantationHealthy volunteersMetagenomics16S rRNA gene sequencingShotgun sequencingMetagenome-assembled genome